The estimated Net Worth of Arthur M Krieg is at least $8.57 Milione dollars as of 18 June 2021. Dr Krieg owns over 7,224 units of Checkmate Pharmaceuticals stock worth over $8,565,207 and over the last 11 years he sold CMPI stock worth over $0. In addition, he makes $0 as Founder, Chief Scientific Officer, Treasurer e Sec. & Independent Director at Checkmate Pharmaceuticals.
Sign up
Dr Krieg CMPI stock SEC Form 4 insiders trading
Dr has made over 10 trades of the Checkmate Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 7,224 units of CMPI stock worth $43,633 on 18 June 2021.
The largest trade he's ever made was buying 33,220 units of Checkmate Pharmaceuticals stock on 29 March 2021 worth over $370,735. On average, Dr trades about 7,928 units every 15 days since 2014. As of 18 June 2021 he still owns at least 815,734 units of Checkmate Pharmaceuticals stock.
You can see the complete history of Dr Krieg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Arthur M. Krieg biography
Dr. Arthur M. Krieg is the Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director at Checkmate Pharmaceuticals.
How old is Dr Krieg?
Dr Krieg is 64, he's been the Founder, Chief Scientific Officer, Treasurer e Sec. & Independent Director of Checkmate Pharmaceuticals since . There are no older and 4 younger executives at Checkmate Pharmaceuticals.
What's Dr Krieg's mailing address?
Arthur's mailing address filed with the SEC is C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE, MA, 02142.
Insiders trading at Checkmate Pharmaceuticals
Over the last 4 years, insiders at Checkmate Pharmaceuticals have traded over $15,801,789 worth of Checkmate Pharmaceuticals stock and bought 928,470 units worth $13,457,615 . The most active insiders traders include Holdings A/S Novo, Global Strategic Fund Ii L.... e Michael Powell. On average, Checkmate Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $1,077,132. The most recent stock trade was executed by Global Strategic Fund Ii L.... on 13 May 2022, trading 131,650 units of CMPI stock currently worth $1,375,743.
What does Checkmate Pharmaceuticals do?
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Checkmate Pharmaceuticals's logo look like?
Complete history of Dr Krieg stock trades at Sarepta Therapeutics Inc e Checkmate Pharmaceuticals
Checkmate Pharmaceuticals executives and stock owners
Checkmate Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. James E. Wooldridge M.D.,
Chief Medical Officer -
Dr. Kleem Chaudhary Ph.D.,
Chief Bus. Officer -
Alan Fuhrman,
Interim CEO, Pres & Director -
Dr. Arthur M. Krieg,
Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director -
Katherine A. Eade,
Gen. Counsel -
Robert F. Dolski,
CFO & Principal Accounting Officer -
Arthur M Krieg,
Chief Scientific Officer -
Joy Yan,
Director -
Holdings A/S Novo,
10% owner -
Barry Labinger,
President and CEO -
Kleem Chaudhary,
Chief Business Officer -
Karen Brennan,
Chief Operating Officer -
Global Strategic Fund Ii L....,
-
Michael Sofinnova Venture P...,
-
Michael Powell,
Director -
Keith T. Flaherty,
Director -
Oren Isacoff,
Director -
Peter Colabuono,
Director -
Robert Dolski,
Chief Financial Officer -
Alan Fuhrman,
Director -
Jon Marc Wigginton,
Director -
Alan Bash,
Chief Executive Officer